Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study

Maria Rita Bongiorno, Costanzo, Marzano, Prignano, Valentina Dini, Fania, Bianchini, Bettoli, Giovanni Casazza, Genovese, Bianchi, Salvatore Cannavò, Atzori, Moltrasio, Bianchini, Serafinella Cannavò, Sirna, Dapavo, Fabbrocini, OffidaniGiuseppe Micali, Ketty Peris, Annalisa Patrizi, Venturini, Gisondi, Alessandro De Patrizio, Rosa Sirna, Viviana Medini

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.
Original languageEnglish
Number of pages20
JournalBritish Journal of Dermatology
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Dermatology

Fingerprint Dive into the research topics of 'Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study'. Together they form a unique fingerprint.

Cite this